Compare WGO & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | PHAT |
|---|---|---|
| Founded | 1958 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2019 |
| Metric | WGO | PHAT |
|---|---|---|
| Price | $48.69 | $12.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $43.36 | $17.33 |
| AVG Volume (30 Days) | 630.2K | ★ 1.4M |
| Earning Date | 12-19-2025 | 03-05-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $2,875,300,000.00 | $147,190,000.00 |
| Revenue This Year | $5.64 | $221.76 |
| Revenue Next Year | $4.80 | $81.67 |
| P/E Ratio | $38.15 | ★ N/A |
| Revenue Growth | 1.38 | ★ 460.30 |
| 52 Week Low | $28.00 | $2.21 |
| 52 Week High | $50.16 | $18.31 |
| Indicator | WGO | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 65.40 | 38.99 |
| Support Level | $44.58 | $12.22 |
| Resistance Level | $50.16 | $14.53 |
| Average True Range (ATR) | 1.67 | 0.84 |
| MACD | 0.03 | -0.12 |
| Stochastic Oscillator | 84.50 | 27.29 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.